Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Sympathetic Nervous System

Central Action of Increased Osmolality to Support Blood Pressure in Deoxycorticosterone Acetate–Salt Rats

Theresa L. O’Donaughy, Yue Qi, Virginia L. Brooks
Download PDF
https://doi.org/10.1161/01.HYP.0000238140.06251.7a
Hypertension. 2006;48:658-663
Originally published September 21, 2006
Theresa L. O’Donaughy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yue Qi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Virginia L. Brooks
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

To test the hypothesis that increased osmolality contributes to hypertension in deoxycorticosterone acetate (DOCA)-salt–hypertensive rats by acting in the brain, DOCA-salt and Sham-salt rats were instrumented with bilateral, nonoccluding intracarotid and femoral catheters. Two weeks prior, rats were uninephrectomized and received subcutaneous implants with or without DOCA (65 mg) and began drinking salt water (1% NaCl and 0.2% KCl). DOCA-salt rats (n=28) exhibited elevated blood pressure (159±4 mm Hg; P<0.05) and heart rate (392±10 bpm; P<0.05) compared with Sham-salt animals (n=5; blood pressure: 107±5 mm Hg; heart rate: 355±10 bpm). Bilateral intracarotid infusion of hypotonic fluid (osmolality: ≈40 mOsm/L), which lowers osmolality of blood to the brain by ≈2%, rapidly decreased blood pressure in DOCA-salt rats (−22±4 mm Hg after 15 minutes; P<0.05; n=7) but not Sham-salt rats (2±2 mm Hg; n=5). Hypotonic fluid infused intravenously did not lower blood pressure (0±2 mm Hg) in DOCA-salt rats (n=7). In DOCA-salt rats pretreated with a V1 vasopressin antagonist (Manning compound, 5 μg, IV), intracarotid hypotonic infusion still decreased blood pressure (−10±3 mm Hg; P<0.05; n=9), but the response was smaller (P<0.05). Finally, in DOCA-salt rats (n=4) pretreated with the V1 antagonist and the ganglionic blocker hexamethonium, decreasing osmolality of blood to the brain did not reduce blood pressure. These data indicate that, in DOCA-salt rats, hypertonicity acts in the brain to support blood pressure, in part by stimulating vasopressin secretion and in part by stimulating another rapidly reversible mechanism, likely the sympathetic nervous system.

  • hypertension, sodium-dependent
  • central nervous system
  • hypertension, mineralocorticoid
  • sodium
  • sympathetic nervous system
  • vasopressin

Increasing evidence supports a role for body fluid osmolality (OSM) in the regulation of blood pressure (BP) and sympathetic nerve activity (for reviews see References1,2). Acute increases in OSM rapidly elevate BP and sympathetic nerve activity to specific beds,3–5 and more chronic increases in plasma OSM, such as during water deprivation, seem to sustain this rapid sympathoexcitation.6 Moreover, recent studies suggest that increased OSM contributes to sympathoexcitation in at least one model of salt-sensitive hypertension, the deoxycorticosterone-treated rat consuming excess salt (DOCA-salt) rat. More specifically, DOCA-salt rats exhibit hypertension and elevated OSM and/or NaCl levels,7–10 and normalization of OSM results in profound decreases in BP and lumbar sympathetic nerve activity.8 However, the site at which OSM is sensed to trigger sustained sympathoexcitation in DOCA-salt rats has not been identified.

Osmoreceptors are present in numerous organs, including the liver, kidney, and brain, but significant indirect evidence implicates the brain in this action. First, forebrain circumventricular organs contain osmoreceptors that are exquisitely sensitive to minute changes in OSM.11 Second, forebrain osmoreceptors mediate the pressor and sympathoexcitatory effects of OSM during water deprivation.12 Therefore, we hypothesized that during DOCA-salt hypertension, increased OSM acts in the brain to increase sympathetic nerve activity and BP. To test this hypothesis, we determined whether acute reduction of the OSM of blood perfusing the brain, by infusion of hypotonic fluid via nonoccluding carotid artery catheters, decreases BP more in DOCA-salt rats than in Sham-salt rats.

Methods

Animals

Male Sprague–Dawley rats weighing between 275 and 375 g (Sasco, Wilmington, MA) were housed in pairs in Plexiglas cages in the animal care unit with ad libitum access to a 0.4% NaCl diet (Harlan Teklad) and deionized water for at least a week before any surgeries were performed. The facility was maintained at a constant temperature of 22±2°C with a 12:12-hour light–dark cycle. All of the procedures were conducted in accordance with the NIH Guide for the Health and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the Oregon Health and Science University.

Surgery

Animals were anesthetized with 2% isoflurane in oxygen. A 1.5-cm incision was made in the skin above the right kidney. After blunt dissection through the muscle layer, the kidney was exteriorized, tied off, and removed. The muscle layer was sutured, and a thin silicone pellet (≈3 cm diameter) with (DOCA) or without (Sham) 65 mg of DOCA was placed dorsally under the skin. The skin was then sutured closed, and rats were given ≈2 weeks to recover. During recovery, and for the duration of the experiment, all of the animals drank water containing 1% NaCl and 0.2% KCl.

Three to 6 days before experimentation, animals were instrumented with femoral arterial and venous catheters for measurement of arterial pressure and for infusions, respectively, and bilateral intracarotid (IC) catheters as described previously.12 Briefly, after rats were anesthetized with 2% isoflurane in oxygen, the femoral catheters were implanted. Bilateral nonocclusive IC catheters were then positioned into the common carotid with the tip pointed toward the brain and secured in place with Vet Bond (3M, Animal Care Products). The external carotid and occipital arteries were ligated to ensure that infused fluids were directed to the brain. Distal ends of the catheters were tunneled subcutaneously to exit at the nape of the neck, and all of the incisions were sutured closed. When not in use, catheters were filled with heparinized isotonic saline (500 U/mL, IC catheters; 200 U/mL, femoral catheters). To maintain patency, IC catheters were flushed daily, and femoral catheters were flushed every 2 days.

Data Acquisition

During experiments, BP and heart rate (HR) were continually recorded via the femoral arterial catheter using a Statham (Spectramed) or Transpac IV (disposable) pressure transducer, a Grass bridge amplifier (7P1), and a Grass polygraph (7D). The pulsatile signal was also fed to a Grass tachograph amplifier (7P4) for determination of HR.

Experimental Protocols

On the experimental day, vascular catheters were connected to recording equipment between 9:00 and 10:00 am, while the rats rested, unrestrained in their home cages. Animals were allowed at least a 1-hour habituation before the start of the protocol. During this time, a baseline blood sample (350 μL) was drawn for measurement of basal hematocrit and plasma protein, Na, Cl, and OSM. Blood was replaced with an equal volume of isotonic saline. At least 30 minutes after the blood draw, when the animal was resting quietly, one of the following protocols was performed.

Protocol 1

This protocol tested the hypothesis that during DOCA-salt hypertension, increased OSM acts in the brain to support BP. To test this hypothesis, it was determined in DOCA-salt rats whether IC infusion of hypotonic fluid decreases BP. The composition of the hypotonic fluid was (in mmol/L): KCl: 4; CaCl2: 2.2; MgCl2: 0.9; Na2HPO4: 1.3; and NaHCO3: 20; the measured OSM was ≈40 mOsm/kg H2O. The pH of the fluid was adjusted to 7.4 before each use. Control measurements of BP and HR were recorded for 15 minutes, while rats remained quiet and usually asleep. Bilateral IC infusion of hypotonic fluid then commenced at 0.1 mL/min per artery; this rate is estimated to decrease blood OSM initially by ≈2%.12 When the infusion was begun, most rats moved for a few minutes before settling back down; data were not collected while the rats were moving. After 15 minutes, the infusion was stopped, and measurements were continued during a 15-minute recovery period. To determine the extent to which the central hypotonic infusion spilled over into the general circulation, a second blood sample was then collected and replaced as for the first blood sample. An identical protocol was performed in a separate group of Sham-salt rats.

Protocol 2

To establish that effects of IC infusion of the hypotonic fluid are because of an action in the brain, the fluid was infused IV (0.2 mL/min) in a separate group of DOCA-salt rats.

Protocol 3

To determine whether changes in BP and HR are secondary to changes in plasma vasopressin concentration, DOCA-salts rats were pretreated with the V1 vasopressin antagonist (Manning Compound, 5 μg IV) 15 to 30 minutes before IC infusion of the hypotonic fluid as in protocol 1.

Protocol 4

To investigate the contribution of the sympathetic nervous system, a final group of DOCA-salt rats was pretreated with the V1 vasopressin antagonist before infusion of the ganglionic blocker hexamethonium (30 mg/kg). Once stable postblockade baseline hemodynamic parameters were achieved, the IC hypotonic infusion was administered as in protocol 1.

Blood Analyses

Plasma electrolytes were either measured from whole blood samples using a Nova CRT electrolyte analyzer (Nova Biomedical Corporation) or from plasma with a Beckman Lablyte System (model 810, Beckman Instruments). Plasma OSM was determined from triplicate 20-μL plasma samples using a micro-osmometer (Model 3300, Advanced Instruments). Duplicate hematocrit tubes were filled with ≈30 μL of arterial blood and spun. Hematocrit was determined with an Adams microhematocrit reader. Tubes were then broken, and the plasma was used for determination of plasma protein with either a SUR-Ne (Atago Instrumentation) or a Hitachi (National Instruments) handheld protein refractometer.

Statistical Analysis

All of the data are presented as mean±SE. Statistical analyses were performed using GB Stat v 7.0 software (Dynamic Microsystems). Baseline blood values were compared using Student’s t tests. Changes in BP and HR secondary to administration of the V1 vasopressin antagonist or hexamethonium were determined using paired t tests. Two-way ANOVA for repeated measures on all 5 of the groups was used to determine changes in BP, HR, and blood chemistries following infusion of hypotonic fluid. In cases in which significant interactions were evident, a Bonferroni post hoc test was performed to determine specific differences. Significance was indicated by P<0.05.

Results

Baseline Values

As summarized in Table 1, DOCA-salt rats exhibited hypertension and basal tachycardia relative to Sham-salt rats, but plasma Cl and protein concentrations and hematocrit were not different between groups. OSM and Na levels tended to be elevated in the DOCA-salt animals, but these differences did not achieve statistical significance.

View this table:
  • View inline
  • View popup

TABLE 1. Baseline Blood Parameters

Effects of Decreasing Central Osmolality in DOCA- and Sham-Salt Rats

BP was unaltered by IC hypotonic infusion in the Sham-salt animals (Figure 1). In contrast, BP rapidly decreased when the hypotonic fluid was infused IC in DOCA-salt rats and rebounded to control levels immediately on cessation of central hypotonic infusion (Figure 1). HR did not change significantly in either DOCA-salt or Sham-salt animals (Figure 1).

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Effect of IC or IV hypotonic fluid infusion on mean arterial pressure (MAP) and HR in DOCA-salt and Sham-salt rats. *P<0.05, within group. #P<0.05, between groups separated by # (DOCA-salt IC and other 2 groups).

As summarized in Table 2, the IC hypotonic infusion decreased plasma protein and Cl concentrations, OSM, and hematocrit (ANOVA, time and interaction: P<0.05), indicating significant systemic recirculation of the infused fluid; plasma Na levels also tended to fall, but this did not reach statistical significance (ANOVA, time: P=0.08). Nevertheless, no differences in these changes were observed between DOCA-salt rats receiving the IC hypotonic infusion and the other groups. Therefore, because of the recirculation, to establish a central site of action, a second group of DOCA-salt rats was infused with the hypotonic fluid IV. Despite similar decreases in plasma OSM, neither HR nor BP changed with IV hypotonic infusion (Figure 1).

View this table:
  • View inline
  • View popup

TABLE 2. Change in Blood Parameters With Hypotonic Infusion

Effect of Decreasing Central Osmolality in V1-Blocked DOCA-Salt Rats

Administration of the V1 vasopressin antagonist significantly decreased BP (158±8 to 146±7 mm Hg; P<0.05) and tended to increase HR (382±10 to 401±5 bpm; P=0.07). Hypotonic fluid infusion into the carotid arteries of V1 vasopressin-blocked DOCA-salt animals still produced a rapid and significant decrease in BP; however, the ultimate fall in pressure was significantly smaller than in the DOCA-salt animals not receiving the V1 antagonist (Figure 2). HR did not change with the fluid infusion (Figure 2). These data reveal that both vasopressin and another rapidly reversible component contribute to central OSM-induced hypertension.

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Effect of intracarotid hypotonic fluid infusion on mean arterial pressure (MAP) and HR in DOCA-salt rats either untreated (Intact) or pretreated with a V1 vasopressin antagonist (V1 blocked) or with hexamethonium and the V1 antagonist (ganglionic and V1 blocked). *P<0.05, within group. #P<0.05, between groups separated by # (DOCA-salt IC and other 2 groups; ganglionic and V1 blocked and other 2 groups).

Effect of Decreasing Central Osmolality in V1-Ganglionic–Blocked DOCA-Salt Rats

Treatment of DOCA-salt rats with both the V1 vasopressin antagonist and the ganglionic blocker hexamethonium chloride resulted in dramatic hypotension (149±13 to 51±4 mm Hg; P<0.05). HR also fell, although the decrease did not quite achieve significance (392±19 to 310±25 bpm; P=0.054).

In rats in which both vasopressin and the autonomic nervous system were blocked, BP did not decrease further with hypotonic IC infusion (Figure 2). HR did not change with IC hypotonic fluid infusion, although it was lower relative to the response in the DOCA-salt intact rats (Figure 2). Osmolality did not fall with infusion of hypotonic fluid (Table 2), which is likely because of increased plasma solutes in response to the hypotension.13–15 Thus, these data suggest that a decrease in sympathetic activity also contributes to the depressor response when the OSM of blood perfusing the brain is decreased in DOCA-salt rats.

Discussion

The goal of this study was to examine the central actions of increased OSM on BP in the DOCA-salt model of salt-sensitive hypertension. The major new findings are: (1) reductions in OSM of blood perfusing the brain via IC infusion of hypotonic fluid decreased BP in DOCA-salt but not Sham-salt animals; (2) intravenous infusion of the hypotonic fluid did not alter BP in DOCA-salt rats; (3) blockade of V1 vasopressin receptors attenuated but did not eliminate the hypotonic infusion-induced depressor response; and (4) blockade of both V1 vasopressin receptors and sympathetic ganglia completely eliminated the depressor response. These data support the hypothesis that, in the salt-sensitive DOCA-salt model of hypertension, increased OSM acts in the brain to support elevated BP, in part by stimulating vasopressin release and in part by activation of the sympathetic nervous system.

Several factors contribute to hypertension development in DOCA-salt–treated animals, including volume expansion and increases in vasopressin and sympathetic activity.16–19 Until recently, the etiology of the sympathoexcitation had been largely unknown; however, our recent studies indicate that increased plasma NaCl levels drive lumbar sympathetic nerve activity and the hypertension.8 Nevertheless, the question of the site at which these changes in OSM are sensed remained unanswered.

Previous work implicates central osmoreceptors. First, increased OSM acting centrally is pressor in part by increasing arginine vasopressin release20 and in part by activation of the sympathetic nervous system.1 Second, Pennington and McKinley21 reported that, in aldosterone-treated sheep, reduction of brain OSM by intracerebroventricular infusion of mannitol slowly decreases BP. Third, in DOCA-treated rats consuming excess salt, c-fos expression is induced in multiple osmosensitive circumventricular organs,11 brain regions lacking a blood–brain barrier. Moreover, we demonstrated recently that in water-deprived rats, lowering OSM of blood perfusing the brain, by bilateral IC infusion of hypotonic fluid, decreases BP and lumbar sympathetic nerve activity, suggesting that increased OSM acts centrally to support arterial pressure in these normotensive animals.12

The present results indicate that activation of brain osmoreceptors also underlies a significant component of the hypertension in DOCA-salt rats. Specifically, we found that a decrease in OSM of blood perfusing the brain, by IC infusion of hypotonic fluid, produced a prompt decrease in BP of ≈25 mm Hg. A similar IV infusion was without effect, indicating the central site of action. Interestingly, whereas we and others have observed small but significant increases in plasma OSM or Na levels in the DOCA-salt animals compared with Sham-salt controls,7–10 in the current study, OSM and Na were insignificantly increased by <2%. Earlier studies have also failed to detect significant increases in plasma Na concentration (eg, see References 22–24). Yet, despite the small magnitude, our data clearly suggest that these extremely small, at times undetectable, elevations in OSM are sufficient to produce hypertension. Previous work provides an explanation for this potency. First, the pressor and sympathoexcitatory effects of intracerebroventricular or IV hypertonic saline administration are increased in rats with elevated mineralocorticoid levels.25,26 Moreover, we found that the ability of chronic increases in OSM to support lumbar sympathetic nerve activity and hypertension were appreciably greater in DOCA-salt rats compared with rats made similarly hyperosmotic by consumption of hypertonic 1.7% saline in the absence of DOCA. Thus, it seems that high mineralocorticoid levels amplify the sympathoexcitatory actions of chronic increases in OSM, such that even undetectable OSM increases become powerfully pressor.

The exact brain site(s) at which OSM is detected and the mechanism by which this signal is amplified by DOCA is unknown. In addition, the present experiments do not reveal whether it is OSM, Na, or an interaction that is sensed.2 Nevertheless, it is noteworthy that the carotid arteries do not perfuse the hindbrain,27,28 implicating forebrain osmoreceptors, such as the organum vasculosum of the lamina terminalis (OVLT) and the subfornical organ, in the hypertensive action of salt.11 Indeed, previous work indicates that very slight increases in plasma NaCl activate OVLT neurons that project to pressure-regulating regions of the hypothalamus.29,30 After forebrain osmoreception, indirect evidence suggests that the paraventricular nucleus (PVN) may then convey the signal to sympathetic preganglionic neurons. First, the PVN receives inputs from forebrain osmosensitive sites.1,31,32 Second, rats receiving subcutaneous injections of DOCA and ingesting hypertonic saline express far more c-fos in the PVN than in most other brain regions, suggesting that this brain region is activated.33 Third, lesions of the PVN reduce BP in DOCA-salt rats,34,35 and acute blockade of the PVN by microinjection of muscimol decreases BP in another model of SSH, Dahl-salt sensitive rats.36 Similarly, during water deprivation, a physiological model of chronically increased NaCl and mineralocorticoids, PVN microinjection of muscimol, decreases BP, lumbar sympathetic nerve activity, and, to a lesser extent, renal nerve activity, and c-fos expression is induced in PVN neurons projecting to the rostral ventrolateral medulla and spinal cord.37–39 Finally, blockade of angiotensin II type 1 receptors in the PVN attenuates the pressor and sympathoexcitatory effect of IC injection of hyperosmotic solutions,40 supporting the hypothesis that recruitment of PVN is involved in this osmotic response.

Experiments were performed in this study to investigate the participation of vasopressin in the observed depressor response. As would be expected in this model,16 there is a significant vasopressin component of the hypertension as evidenced by the significant fall in pressure after administration of the antagonist. In addition, approximately half of the depressor response produced by lowering central OSM can be explained by the actions of vasopressin. Indeed, the time course of the fall in pressure following decreased central OSM in the intact DOCA-salt animal seemed to be biphasic. The later phase, starting ≈9 minutes after initiating the infusion, was eliminated by previous V1 vasopressin blockade, indicating that it was because of removal of vasopressinergic inputs. This time course is consistent with the half-life of vasopressin of a few minutes.41–43 On the other hand, based on the rapid time course, the initial immediate fall is likely because of sympathetic withdrawal. This conclusion is supported by the studies in animals in which both the vasopressin and sympathetic inputs were blocked, because decreasing forebrain OSM had no further effect on BP. The caveat to these experiments, of course, is that the starting BP in these animals is significantly lower than in the ganglionic intact animals. Nevertheless, there are other factors that could support BP in this setting, such as angiotensin II44; therefore, we conclude that increased OSM does not seem to act via these additional factors. These data, taken in combination with our previous work showing that systemic infusion of hypotonic fluid rapidly decreases sympathetic activity,8 support the hypothesis that, in DOCA-salt rats, central osmoreceptor activation drives hypertension both by increasing vasopressin release and also by increasing sympathetic activity.8

Perspectives

Our recent studies implicate a central action of hypertonicity as key in the sympathoexcitation and hypertension induced in one model of salt-sensitive hypertension, the DOCA-salt rat. A question that naturally follows is whether a similar mechanism underlies sympathoexcitation in other salt-sensitive models. We have proposed previously a unifying hypothesis that predicts that the elevation in sympathetic tone is mediated by a failure of increased salt intake to adequately suppress sympathoexcitatory actions of systemic or brain-generated angiotensin.2,45 In addition, the relatively high angiotensin levels amplify the excitatory effects of increased OSM on the sympathetic nervous system. In support of this hypothesis, it is noteworthy that most, if not all, salt-sensitive models, including DOCA-salt,46–52 are associated with inappropriately elevated levels or actions of angiotensin. Nevertheless, significant research that involves studies of other salt-sensitive models is required before this hypothesis can be established.

Acknowledgments

Sources of Funding

This work was supported in part by the National Institutes of Health grants HL-35872 and HL-70962. T.L.O. was supported in part by a fellowship from the American Heart Association (0325552Z).

Disclosures

None.

  • Received March 29, 2006.
  • Revision received April 18, 2006.
  • Accepted July 18, 2006.

References

  1. ↵
    Toney GM, Chen QH, Cato MJ, Stocker SD. Central osmotic regulation of sympathetic nerve activity. Acta Physiol Scand. 2003; 177: 43–55.
    OpenUrlCrossRefPubMed
  2. ↵
    Brooks VL, Haywood JR, Johnson AK. Translation of salt retention to central activation of the sympathetic nervous system in hypertension. Clin Exp Pharmacol Physiol. 2005; 32: 426–432.
    OpenUrlCrossRefPubMed
  3. ↵
    Garcia-Estan J, Carbonell LF, Garcia-Salom M, Salazar FJ, Quesada T. Hemodynamic effects of hypertonic saline in the conscious rat. Life Sci. 1989; 44: 1343–1350.
    OpenUrlCrossRefPubMed
  4. ↵
    Bealer SL, Delle M, Skarphedinsson JO, Carlsson S, Thoren P. Differential responses in adrenal and renal nerves to CNS osmotic stimulation. Brain Res Bull. 1996; 39: 205–209.
    OpenUrlCrossRefPubMed
  5. ↵
    Weiss ML, Claassen DE, Hirai T, Kenney MJ. Nonuniform sympathetic nerve responses to intravenous hypertonic saline infusion. J Auton Nerv Syst. 1996; 57: 109–115.
    OpenUrlCrossRefPubMed
  6. ↵
    Scrogin KE, Grygielko ET, Brooks VL. Osmolality: A physiological long-term regulator of lumbar sympathetic nerve activity and arterial pressure. Am J Physiol. 1999; 276: R1579–R1586.
    OpenUrlPubMed
  7. ↵
    Trinder D, Phillips PA, Risvanis J, Stephenson JM, Johnston CI. Regulation of vasopressin receptors in deoxycorticosterone acetate-salt hypertension. Hypertension. 1992; 20: 569–574.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    O’Donaughy TL, Brooks VL. Deoxycorticosterone acetate-salt rats. Hypertension and sympathoexcitation driven by increased NaCl levels. Hypertension. 2006; 47: 680–685.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Tajima Y, Ichikawa S, Sakamaki T, Matsuo H, Aizawa F, Kogure M, Yagi S, Murata K. Body fluid distribution in the maintenance of DOCA-salt hypertension in rats. Am J Physiol. 1983; 244: H695–H700.
    OpenUrlPubMed
  10. ↵
    Titze J, Bauer K, Schafflhuber M, Dietsch P, Lang R, Schwind KH, Luft FC, Eckardt KU, Hilgers KF. Internal sodium balance in DOCA-salt rats: a body composition study. Am J Physiol Renal Physiol. 2005; 289: F793–F802.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    McKinley MJ, Johnson AK. The physiological regulation of thirst and fluid intake. News Physiol Sci. 2004; 19: 1–6.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Brooks VL, Qi Y, O’Donaughy TL. Increased osmolality of conscious water-deprived rats supports arterial pressure and sympathetic activity via a brain action. Am J Physiol Regul Integr Comp Physiol. 2005; 288: R1248–R1255.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Gann DS, Carlson DE, Byrnes GJ, Pirkle JC Jr, Allen-Rowlands CF. Role of solute in the early restitution of blood volume after hemorrhage. Surgery. 1983; 94: 439–446.
    OpenUrlPubMed
  14. ↵
    Silveira SA, Haibara AS, Coimbra CC. Hyperglycemic response to hemorrhage is modulated by baroreceptors unloading but not by peripheral chemoreceptors activation. Auton Neurosci. 2005; 123: 36–43.
    OpenUrlCrossRefPubMed
  15. ↵
    Byrnes GJ, Engeland WC, Gann DS. Restitution of blood volume after hemorrhage: inhibition by somatostatin. Endocrinology. 1982; 110: 1945–1949.
    OpenUrlCrossRefPubMed
  16. ↵
    Kunes J, Nedvidek J, Zicha J. Vasopressin and water distribution in rats with DOCA-salt hypertension. J Hypertens Suppl. 1989; 7: S204–S205.
    OpenUrlPubMed
  17. ↵
    Iriuchijima J, Mizogami S, Sokabe H. Sympathetic nervous activity in renal and DOC hypertensive rats. Jpn Heart J. 1975; 16: 36–43.
    OpenUrlPubMed
  18. ↵
    de Champlain J, Bouvier M, Drolet G. Abnormal regulation of the sympathoadrenal system in deoxycorticosterone acetate-salt hypertensive rats. Can J Physiol Pharmacol. 1987; 65: 1605–1614.
    OpenUrlCrossRefPubMed
  19. ↵
    Gomez-Sanchez CE, Gomez-Sanchez EP. Role of central mineralocorticoid receptors in cardiovascular disease. Curr Hypertens Rep. 2001; 3: 263–269.
    OpenUrlPubMed
  20. ↵
    Andersson B, Olsson K. On central control of body fluid homeostasis. Cond Reflex. 1973; 8: 147–159.
    OpenUrlPubMed
  21. ↵
    Pennington GL, McKinley MJ. Reduction of cerebral NaCl concentration can abolish mineralocorticoid escape. Am J Physiol. 1990; 259: F839–F846.
    OpenUrlPubMed
  22. ↵
    Fernandes S, Bruneval P, Hagege A, Heudes D, Ghostine S, Bouby N. Chronic V2 vasopressin receptor stimulation increases basal blood pressure and exacerbates deoxycorticosterone acetate-salt hypertension. Endocrinology. 2002; 143: 2759–2766.
    OpenUrlCrossRefPubMed
  23. ↵
    Crofton JT, Share L, Wang BC, Shade RE. Pressor responsiveness to vasopressin in the rat with DOC-salt hypertension. Hypertension. 1980; 2: 424–431.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Chrysant SG, Walsh GM, Frohlich ED, Townsend SM. Hemodynamic changes induced by prolonged NaCl and DOCA administration in spontaneously hypertensive rats. Angiology. 1978; 29: 303–309.
    OpenUrlFREE Full Text
  25. ↵
    Wang H, Huang BS, Leenen FH. Brain sodium channels and ouabainlike compounds mediate central aldosterone-induced hypertension. Am J Physiol Heart Circ Physiol. 2003; 285: H2516–H2523.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Brooks VL, Freeman KL, Qi Y. Time course of synergistic interaction between DOCA and salt on blood pressure: roles of vasopressin and hepatic osmoreceptors. Am J Physiol. 2006; In press.
  27. ↵
    Reid IA, Brooks VL, Rudolph CD, Keil LC. Analysis of the actions of angiotensin on the central nervous system of conscious dogs. Am J Physiol. 1982; 243: R82–R91.
    OpenUrlPubMed
  28. ↵
    Fink GD, Haywood JR, Bryan WJ, Packwood W, Brody MJ. Central site for pressor action of blood-borne angiotensin in rat. Am J Physiol. 1980; 239: R358–R361.
    OpenUrlPubMed
  29. ↵
    Peng N, Wei CC, Oparil S, Wyss JM. The organum vasculosum of the lamina terminalis regulates noradrenaline release in the anterior hypothalamic nucleus. Neuroscience. 2000; 99: 149–156.
    OpenUrlCrossRefPubMed
  30. ↵
    Bourque CW, Oliet SH. Osmoreceptors in the central nervous system. Annu Rev Physiol. 1997; 59: 601–619.
    OpenUrlCrossRefPubMed
  31. ↵
    Larsen PJ, Mikkelsen JD. Functional identification of central afferent projections conveying information of acute “stress” to the hypothalamic paraventricular nucleus. J Neurosci. 1995; 15: 2609–2627.
    OpenUrlAbstract
  32. ↵
    Bains JS, Ferguson AV. Paraventricular nucleus neurons projecting to the spinal cord receive excitatory input from the subfornical organ. Am J Physiol. 1995; 268: R625–R633.
    OpenUrlPubMed
  33. ↵
    Pietranera L, Saravia FE, McEwen BS, Lucas LL, Johnson AK, De Nicola AF. Changes in Fos expression in various brain regions during deoxycorticosterone acetate treatment: relation to salt appetite, vasopressin mRNA and the mineralocorticoid receptor. Neuroendocrinology. 2001; 74: 396–406.
    OpenUrlCrossRefPubMed
  34. ↵
    Nakata T, Takeda K, Itho H, Hirata M, Kawasaki S, Hayashi J, Oguro M, Sasaki S, Nakagawa M. Paraventricular nucleus lesions attenuate the development of hypertension in DOCA/salt-treated rats. Am J Hypertens. 1989; 2: 625–630.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Ciriello J. Contribution of forebrain mechanisms in the maintenance of deoxycorticosterone acetate-salt hypertension. Clin Exp Hypertens A. 1988; 10: 169–178.
    OpenUrlPubMed
  36. ↵
    Ito S, Komatsu K, Tsukamoto K, Kanmatsuse K, Sved AF. Ventrolateral medulla AT1 receptors support blood pressure in hypertensive rats. Hypertension. 2002; 40: 552–559.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Stocker SD, Hunwick KJ, Toney GM. Hypothalamic paraventricular nucleus differentially supports lumbar and renal sympathetic outflow in water-deprived rats. J Physiol. 2005; 563: 249–263.
    OpenUrlCrossRefPubMed
  38. ↵
    Stocker SD, Cunningham JT, Toney GM. Water deprivation increases Fos immunoreactivity in PVN autonomic neurons with projections to the spinal cord and rostral ventrolateral medulla. Am J Physiol Regul Integr Comp Physiol. 2004; 287: R1172–R1183.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Stocker SD, Keith KJ, Toney GM. Acute inhibition of the hypothalamic paraventricular nucleus decreases renal sympathetic nerve activity and arterial blood pressure in water-deprived rats. Am J Physiol Regul Integr Comp Physiol. 2004; 286: R719–R725.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Chen QH, Toney GM. AT(1)-receptor blockade in the hypothalamic PVN reduces central hyperosmolality-induced renal sympathoexcitation. Am J Physiol Regul Integr Comp Physiol. 2001; 281: R1844–R1853.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Janaky T, Laszlo FA, Sirokman F, Morgat JL. Biological half-life and organ distribution of [3H]8-arginine-vasopressin in the rat. J Endocrinol. 1982; 93: 295–303.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Gazis D. Plasma half-lives of vasopressin and oxytocin analogs after iv injection in rats. Proc Soc Exp Biol Med. 1978; 158: 663–665.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Forsling ML, Martin MJ, Sturdy JC, Burton AM. Observations on the release and clearance of neurophysin and the neurohypophysial hormones in the rat. J Endocrinol. 1973; 57: 307–315.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Bennett T, Gardiner SM. Water deprivation: effects on fluid and electrolyte handling and plasma biochemistry in Long-Evans and Brattleboro rats. J Physiol. 1987; 385: 35–48.
    OpenUrlPubMed
  45. ↵
    Brooks VL, Scrogin KE, McKeogh DF. The interaction of angiotensin II and osmolality in the generation of sympathetic tone during changes in dietary salt intake. An hypothesis. Ann N Y Acad Sci. 2001; 940: 380–394.
    OpenUrlPubMed
  46. ↵
    Gutkind JS, Kurihara M, Saavedra JM. Increased angiotensin II receptors in brain nuclei of DOCA-salt hypertensive rats. Am J Physiol. 1988; 255: H646–H650.
    OpenUrlPubMed
  47. ↵
    Nishimura M, Ohtsuka K, Iwai N, Takahashi H, Yoshimura M. Regulation of brain renin-angiotensin system by benzamil-blockable sodium channels. Am J Physiol. 1999; 276: R1416–R1424.
    OpenUrlPubMed
  48. ↵
    Schenk J, McNeill JH. The pathogenesis of DOCA-salt hypertension. J Pharmacol Toxicol Methods. 1992; 27: 161–170.
    OpenUrlCrossRefPubMed
  49. ↵
    Fournie-Zaluski MC, Fassot C, Valentin B, Djordjijevic D, Reaux-Le Goazigo A, Corvol P, Roques BP, Llorens-Cortes C. Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension. Proc Natl Acad Sci U S A. 2004; 101: 7775–7780.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    Kubo T, Yamaguchi H, Tsujimura M, Hagiwara Y, Fukumori R. Blockade of angiotensin receptors in the anterior hypothalamic preoptic area lowers blood pressure in DOCA-salt hypertensive rats. Hypertens Res. 2000; 23: 109–118.
    OpenUrlCrossRefPubMed
  51. ↵
    Nishimura M, Ohtsuka K, Sakamoto M, Nanbu A, Takahashi H, Yoshimura M. Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats. J Hypertens. 1998; 16: 1175–1185.
    OpenUrlPubMed
  52. ↵
    Park CG, Leenen FH. Effects of centrally administered losartan on deoxycorticosterone-salt hypertension rats. J Korean Med Sci. 2001; 16: 553–557.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
October 2006, Volume 48, Issue 4
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Central Action of Increased Osmolality to Support Blood Pressure in Deoxycorticosterone Acetate–Salt Rats
    Theresa L. O’Donaughy, Yue Qi and Virginia L. Brooks
    Hypertension. 2006;48:658-663, originally published September 21, 2006
    https://doi.org/10.1161/01.HYP.0000238140.06251.7a

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Central Action of Increased Osmolality to Support Blood Pressure in Deoxycorticosterone Acetate–Salt Rats
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Central Action of Increased Osmolality to Support Blood Pressure in Deoxycorticosterone Acetate–Salt Rats
    Theresa L. O’Donaughy, Yue Qi and Virginia L. Brooks
    Hypertension. 2006;48:658-663, originally published September 21, 2006
    https://doi.org/10.1161/01.HYP.0000238140.06251.7a
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Cardiology
    • Etiology
      • Hypertension
        • Hypertension

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured